drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Investigational subcutaneous anti-CD38 IgG1 monoclonal antibody expected to mirror daratumumab’s mechanisms (CDC, ADCC, ADCP, apoptosis via Fc cross-linking; depletion of CD38+ immunosuppressive cells).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Anti-CD38 IgG1 monoclonal antibody that binds CD38 on plasma/myeloma and other CD38+ cells, inducing complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), and triggering apoptosis via Fc cross-linking; also depletes CD38+ immunosuppressive cells to enhance antitumor immunity.
drug_name
QL2109
nct_id_drug_ref
NCT06371534